SiO2 company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Corporate Minority | Alive

Total Raised


Last Raised

$100M | 8 mos ago

About SiO2

SiO2 develops and manufactures medical-grade containers with a glass-like barrier to meet the most demanding needs of it's customers and patients.

SiO2 Headquarter Location

2250 Riley Street

Auburn, Alabama, 36832,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing SiO2

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

SiO2 is included in 2 Expert Collections, including Medical Devices.


Medical Devices

8,442 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,900 items

SiO2 Patents

SiO2 has filed 53 patents.

The 3 most popular patent topics include:

  • Drug delivery devices
  • Medical equipment
  • Thin film deposition
patents chart

Application Date

Grant Date


Related Topics




Coatings, Medical terminology, Hematology, Medical equipment, Blood tests


Application Date


Grant Date



Related Topics

Coatings, Medical terminology, Hematology, Medical equipment, Blood tests



Latest SiO2 News

Longhorn Vaccines & Diagnostics and SiO2 Materials Science Team Up to Develop 12 Millimeter Sample Transport Media for Higher Volumes of Automated Virus Testing

Oct 4, 2021

Longhorn’s PrimeStore® MTM Liquid Solution, Combined with SiO2’s Test Tube and Manufacturing Capabilities, Provides Pooling and Higher Output Testing for Large Labs October 04, 2021 08:00 AM Eastern Daylight Time BETHESDA, Md. & AUBURN, Ala.--( BUSINESS WIRE )-- Longhorn Vaccines & Diagnostics , an innovative molecular tool, assay and vaccine development company focused on serving unmet critical needs in both developed and developing nations, and SiO2 Materials Science , a privately-owned U.S. advanced materials science corporation introducing breakthrough disruptive technology for packaging biological pharmaceuticals and vaccines, today announced a partnership to produce and distribute PrimeStore® MTM in SiO2’s proprietary 12 millimeter sample transport tubes. The transport tubes will allow large laboratories with high volumes of sample testing to pool 10 times more samples with 1/10th of the required materials. The sample transport tubes are manufactured by SiO2 and are available now to labs for testing COVID-19, influenza, and other widespread viruses. Throughout the COVID-19 pandemic virus testing has been critical to targeting new cases and assessing the impact of the virus on the global population, and has inspired labs to shift towards higher volumes of testing for both COVID-19 and future virus needs. To further support this trend, the collaboration between Longhorn and SiO2 combines SiO2’s 12 millimeter test tube with Longhorn’s PrimeStore® MTM, which is a patented, FDA-cleared sample collection system that inactivates RNA, mRNA, and DNA pathogens. “We take immense pride in our partnerships, and our collaboration with SiO2 is no different—our companies have come together to meet the needs of virus testing today and prepare for the next pandemic,” said Jeff Fischer, President of Longhorn Vaccines and Diagnostics. “SiO2’s production capabilities are a key reason why we’re working with them; they have the ability to produce millions of tubes per month. By combining our PrimeStore® MTM liquid with SiO2’s 12 millimeter test tube, labs have the ability to test a patient for multiple viruses—one tube can be used to test a patient for COVID-19, influenza A, and influenza B at the same time.” Beyond the ability to test multiple viruses using one tube, labs can use the test results to subtype each virus and see which strains of COVID-19, influenza, respiratory syncytial virus, and other viruses are circulating within a specific population. This will allow the U.S. government to track viral patterns to dispatch appropriate testing and virus prevention. “We reached out to Longhorn in February because we view their sample collection technology as first-in-class when it comes to inactive sample testing. With the availability of the COVID-19 vaccine, now is the time for us to join together to offer a new solution for virus testing at high volumes,” said Lawrence Ganti, President of SiO2 Materials Science. “We can produce up to two and a half million tubes per week, so combining our manufacturing with Longhorn’s technology makes sense for the future of virus testing.” Longhorn was able to scale its operations from 50,000 to 100,000 tubes of PrimeStore® MTM per month prior to March 2020, to weekly shipments exceeding 2 million tubes during the height of COVID-19 in the US, to help the federal government expand its testing capabilities. For more information about Longhorn’s PrimeStore® MTM technology, visit their website at . About Longhorn Vaccines and Diagnostics Longhorn Vaccines & Diagnostics is an innovative molecular tool, assay and vaccine development company focused on serving unmet critical needs in both developed and developing nations. Longhorn’s core product, PrimeStore® Molecular Transport Medium (MTM), is a patented, FDA approved, state-of-the-art ambient temperature molecular diagnostic collection and transport device that can help governments, global health organizations and drug manufacturers improve the diagnosis and treatment of highly infectious diseases such as Influenza, SARS-CoV-2, and Mycobacterium tuberculosis (TB). Unlike standard devices for collecting and transporting TB samples, PrimeStore® MTM is the first molecular transport device that can safely deactivate pathogens and stabilize RNA and DNA, allowing enhanced point of care and ambient temperature transport for laboratory based molecular testing and characterization. Longhorn is based in Bethesda, Maryland. About SiO2 Materials Science Managed by the same family for more than 100 years, SiO2 Materials Science is a privately owned U.S. advanced materials science corporation introducing breakthrough disruptive technology. The company is located in Auburn, Alabama. The company has deep partnerships with leading professors at the foremost research universities such as University of California, University of Chicago, MIT, and CalTech. For more information, visit . Contacts

SiO2 Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

SiO2 Rank

  • When was SiO2 founded?

    SiO2 was founded in 2011.

  • Where is SiO2's headquarters?

    SiO2's headquarters is located at 2250 Riley Street, Auburn.

  • What is SiO2's latest funding round?

    SiO2's latest funding round is Corporate Minority.

  • How much did SiO2 raise?

    SiO2 raised a total of $148M.

  • Who are the investors of SiO2?

    Investors of SiO2 include Doosan , MPM Capital, Novartis Venture Funds and JMC Investment.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.